Effects of losartan on the treatment of posttransplant erythrocytosis.

Abstract

Erythrocytosis is a relatively common complication of renal transplantation. Recent observations indicate that angiotensin-converting enzyme inhibitors correct renal transplant erythrocytosis. Other drugs to inhibit the renin-angiotensin system have been developed recently. The newest of these is losartan, a specific antagonist of the angiotensin II type I receptor. We report three patients in which the use of losartan controlled posttransplant erythrocytosis. Our findings suggest that losartan can be effective and safe in the treatment of posttransplant erythrocytosis.

• Authors: J F Navarro, J García, M Macía, C Mora, J Chahin, E Gallego, M L Méndez, N del Castillo
• Journal: Clinical nephrology (Clin Nephrol) Vol. 49 Issue 6 Pg. 370-2 (Jun 1998) ISSN: 0301-0430 [Print] Germany
• PMID: 9696433 (Publication Type: Case Reports, Journal Article)

Chemical References

• Angiotensin II
• Losartan

Topics

• Adult
• Angiotensin II (antagonists & inhibitors)
• Humans
• Kidney Transplantation (adverse effects)
• Losartan (therapeutic use)
• Male
• Polycythemia (blood, drug therapy, etiology)